Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Invested Capital (2019 - 2023)

Historic Return on Invested Capital for Lineage Cell Therapeutics (LCTX) over the last 6 years, with Q4 2023 value amounting to 0.35%.

  • Lineage Cell Therapeutics' Return on Invested Capital fell 2200.0% to 0.35% in Q4 2023 from the same period last year, while for Dec 2023 it was 0.35%, marking a year-over-year decrease of 2200.0%. This contributed to the annual value of 0.33% for FY2023, which is 600.0% down from last year.
  • As of Q4 2023, Lineage Cell Therapeutics' Return on Invested Capital stood at 0.35%, which was down 2200.0% from 0.34% recorded in Q3 2023.
  • In the past 5 years, Lineage Cell Therapeutics' Return on Invested Capital registered a high of 0.02% during Q3 2021, and its lowest value of 0.4% during Q3 2022.
  • In the last 4 years, Lineage Cell Therapeutics' Return on Invested Capital had a median value of 0.32% in 2023 and averaged 0.27%.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Return on Invested Capital crashed by -3700bps in 2022, and later surged by 600bps in 2023.
  • Quarter analysis of 4 years shows Lineage Cell Therapeutics' Return on Invested Capital stood at 0.21% in 2019, then soared by 89bps to 0.02% in 2021, then plummeted by -480bps to 0.13% in 2022, then crashed by -168bps to 0.35% in 2023.
  • Its Return on Invested Capital was 0.35% in Q4 2023, compared to 0.34% in Q3 2023 and 0.32% in Q2 2023.